Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC2441
Trial ID NCT04532268
Disease B-Cell Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19 CAR-T cells
PhaseEarly_Phase1
Recruitment statusRecruiting
TitleA Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
Year2020
CountryChina
Company sponsorZhejiang University
Other ID(s)hCD19-001

Clinical Result

Cohort 1
Administration route intravenous infusion
Pts 58
Age Child, Adult, Older_Adult
Outcome 54/58(CR/CRi, at 28 days). With a median follow-up of 13.5 months, the estimated 1-year OS and EFS were 73.6% (95% CI 62.1% to 87.4%) and 46.0% (95% CI 33.7% to 62.8%), with a median OS and EFS of 21.5 months and 9.5 months, respectively.
Adverse reactions 21/58(severe cytokine release syndrome); 3/58(severe neurotoxicity)
References PMID: 36808074

Relationship Graph

Overview of Knowledge Graph